Jupiter biotech scores $56M to defeat herpes, in a field littered with failure
Scientists have repeatedly stumbled in their quest to develop a herpes vaccine. Jupiter, Florida-based biotech X-Vax Technology thinks it may have the formula — and now has $56 million in the bank to prove it.
Infection with herpes simplex virus (HSV) types 1 and 2 is endemic to the human population. Although most oral and genital herpes infections are asymptomatic, the viruses can also cause severe diseases such as recurrent keratitis — that can cause blindness — as well as encephalitis, and systemic disease in neonates and immunocompromised patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
